What is the ticker symbol for Voyager Therapeutics?

Voyager Therapeutics trades under the ticker VYGR on NASDAQ.

What sector does Voyager Therapeutics operate in?

Voyager Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze VYGR in a portfolio?

PortView shows VYGR's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

Voyager Therapeutics (VYGR) Stock Analysis

NASDAQHealthcareBiotechnology

$3.48+1.31%

1-year price historyRange $3.00 – $5.33

52-week range$3.48

$2.94$5.55

What Voyager Therapeutics does

Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.

Key metrics

Market cap

$209.96M

P/E (TTM)

-1.93

EPS (TTM)

$-1.80

Beta

1.31

Dividend yield

0.00%

Revenue / share

$0.57

50-day avg

$3.33

200-day avg

$3.78

52-week high

$5.55

52-week low

$2.94

CEO

Alfred W. Sandrock Jr.

ETFs linked to VYGR

Broad-market and Healthcare sector ETFs an investor holding Voyager Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

SPY — SPDR S&P 500 ETF Trust VOO — Vanguard S&P 500 ETF QQQ — Invesco QQQ Trust VTI — Vanguard Total Stock Market ETF

PortView Portfolio Insights

PortView analyzes how VYGR fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze VYGR in PortView →

Similar companies

JNJ — Johnson &LLY — Eli Lilly A — Agilent Technologies ABBV — AbbVie Inc.ABT — Abbott Laboratories ALNY — Alnylam Pharmaceuticals

Frequently asked questions

What is the ticker symbol for Voyager Therapeutics?: Voyager Therapeutics trades under the ticker VYGR on NASDAQ.
Which exchange is VYGR listed on?: VYGR is listed on NASDAQ.
What sector does Voyager Therapeutics operate in?: Voyager Therapeutics is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze VYGR in a portfolio?: PortView shows VYGR's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.